Interim results from Canada’s Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.

The 2019/20 northern hemisphere influenza season has been characterised by early co-circulation of influenza A and B viruses [1-5]. We report interim virological and vaccine effectiveness (VE) findings for the 2019/20 season from the community-based Canadian Sentinel Practitioner Surveillance Network (SPSN).

Study design
VE was estimated using a test-negative design as previously described [6]. Nasal/nasopharyngeal specimens were collected from patients presenting to sentinel sites in the provinces of Alberta, British Columbia, Ontario and Quebec. Patients who were at least 1 year of age and who presented within 7 days of onset of influenza-like illness (ILI) were eligible for inclusion in VE analyses. ILI was defined by self-reported fever and cough and one or more of arthralgia, myalgia, prostration or sore throat. Fever was not a requirement for adults aged ≥ 65 years old. Influenza vaccination status was based on self- (or parent/guardian) report of 2019/20 vaccine receipt ≥ 2 weeks before ILI onset. Specimens were tested for presence of influenza virus by real-time RT-PCR assays. Sanger sequencing of the haemagglutinin (HA) gene was undertaken on a convenience sample of original patient specimens. Amino acid substitutions at HA antigenic sites are hereafter specified in parentheses, those affecting the receptor-binding site as ‘RBS’ and changes associated with potential gain or loss of N-linked glycosylation as ‘+/−CHO’. Viral sequence data were deposited for reference into the Global Initiative on Sharing All Influenza Data (GISAID) platform (www.gisaid.org) under accession numbers EPI_ISL_41122–411846. Antigenic characterisation of a convenience sample of virus isolates was undertaken by haemagglutination inhibition (HI) assay using post-infection ferret anti-sera raised to egg-passaged influenza A and cell-passaged influenza B vaccine reference strains, conducted as previously described [6-8].

Adjusted odds ratios (OR) for influenza test-positivity between vaccinated and unvaccinated participants were derived using a logistic regression model. VE was calculated as (1 – adjusted OR) × 100%.

Ethical statement
The 2019/20 VE study protocol was approved by ethics review committees: University of Calgary, Calgary, Alberta (REB15-0587_MOD9); University of Alberta,
Influenza vaccine components and formulations

For the 2019/20 influenza vaccine, the World Health Organization recommended update to both influenza A vaccine components from the prior 2018/19 season, changing from clade 6B.1 to a clade 6B.1A1 strain for A(H1N1)pdm09 (A/Brisbane/02/2018-like); and from clade 3C.2a1 to a clade 3C.3a strain for A(H3N2) (A/Kansas/14/2017-like) [9,10]. The influenza B vaccine components were unchanged from the prior season: trivalent vaccine included a B/Victoria-lineage clade V1A.1 (Δ2) strain (B/Colorado/06/2017-like) defined by a double amino-acid deletion in the 160-loop of the HA protein; quadrivalent influenza vaccine additionally included a clade 3 B/Yamagata-lineage virus (B/Phuket/3073/2013-like) [9,10].

All influenza vaccines used in Canada were manufactured in eggs and inactivated. Overall and by province ≥74% of publicly-funded doses were quadrivalent except in British Columbia where 16% of doses overall were quadrivalent and targeted to children. In Ontario high-dose trivalent vaccine was publicly funded for elderly adults aged ≥ 65 years old.

Study period and influenza detection

The study period spanned specimen collection dates from 1 November 2019 (week 44) to 1 February 2020 (week 5) during which 2,808 specimens were included for analysis. These six viruses from three specimens are each plotted separately giving 2,811 displayed specimens rather than 2,808.

Missing specimen collection dates were imputed as the date the specimen was received and processed at the provincial laboratory minus 2 days.
### Table 1
Interim vaccine effectiveness (VE) estimates against influenza, Canadian Sentinel Practitioner Surveillance Network (SPSN), 1 November 2019–1 February 2020 (n = 2,808)

| Influenza outcome | Age group (years) | Total | Cases | Controls | Adjusted VE %a,b,c | 95% CI |
|-------------------|------------------|-------|-------|----------|-------------------|-------|
|                   |                  |       | All   | Vaccinated | %     | All   | Vaccinated | %     |
| Any A or Bd       | All ages         | 2,808 | 1,411 | 191       | 14    | 1,397 | 399        | 29    | 58    | 47 to 66 |
|                   | 1–19             | 866   | 512   | 33        | 6     | 354   | 70         | 20    | 74    | 59 to 84 |
|                   | 20–64            | 1,718 | 841   | 122       | 15    | 877   | 229        | 26    | 55    | 41 to 66 |
|                   | ≥65              | 224   | 58    | 36        | 62    | 166   | 100        | 60    | 18    | −59 to 58 |
| Influenza A       | All ages         | 2,128 | 731   | 131       | 18    | 1,397 | 399        | 29    | 49    | 34 to 60 |
|                   | 1–19             | 543   | 189   | 15        | 8     | 354   | 70         | 20    | 70    | 44 to 84 |
|                   | 20–64            | 1,372 | 495   | 88        | 18    | 877   | 229        | 26    | 45    | 25 to 59 |
|                   | ≥65              | 213   | 47    | 28        | ND    | 166   | 100        | 60    | NE    |           |
| A(H1N1)pdm09      | All ages         | 1,948 | 551   | 107       | 19    | 1,397 | 399        | 29    | 44    | 26 to 58 |
|                   | 1–19             | 478   | 124   | 13        | 10    | 354   | 70         | 20    | 63    | 25 to 81 |
|                   | 20–64            | 1,273 | 396   | 75        | 19    | 877   | 229        | 26    | 39    | 14 to 56 |
|                   | ≥65              | 197   | 31    | 19        | ND    | 166   | 100        | 60    | NE    |           |
| A(H3N2)           | All ages         | 1,561 | 164   | 22        | 13    | 1,397 | 399        | 29    | 62    | 37 to 77 |
|                   | 1–19             | 414   | 60    | 2         | 3     | 354   | 70         | 20    | NE    |           |
|                   | 20–64            | 967   | 90    | 11        | 12    | 877   | 229        | 26    | 64    | 29 to 81 |
|                   | ≥65              | 180   | 14    | 9         | ND    | 166   | 100        | 60    | NE    |           |
| Influenza Bf       | All ages         | 2,080 | 683   | 60        | 9     | 1,397 | 399        | 29    | 69    | 57 to 77 |
|                   | 1–19             | 679   | 325   | 18        | 6     | 354   | 70         | 20    | 77    | 59 to 87 |
|                   | 20–64            | 1,224 | 347   | 34        | 10    | 877   | 229        | 26    | 68    | 51 to 79 |
|                   | ≥65              | 177   | 11    | 8         | ND    | 166   | 100        | 60    | NE    |           |

CI: confidence interval; ND: not displayed owing to small denominator; NE: not estimated owing to sparse data; VE: vaccine effectiveness.

a All VE estimates adjusted for age group, province (Alberta, British Columbia, Ontario, Quebec), specimen collection interval (4.5–7 days) and calendar time (modelled as a natural cubic spline with three equally-spaced knots). For all ages, age group adjustment based on 1–8, 9–19, 20–49, 50–64 and ≥65 years. For children 1–19 years old, age adjustment based on 1–8 and 9–19 years. For adults 20–64 years old, age adjustment based on 20–49 and 50–64 years.
b Additional adjustment for comorbidity (yes/no/unknown) and sex (male/female/unknown) did not alter any of the displayed VE estimates by more than 2% (absolute) except where specified.
c Using a later study start date of 1 December 2019 did not alter any of the displayed VE estimates by more than 3% (absolute).
d Excluding the province of British Columbia where a smaller proportion of doses distributed were quadrivalent, the VE estimate for all ages was unchanged and age-stratified estimates remained within 4% (absolute) of those displayed.
e With additional adjustment for comorbidity (yes/no/unknown) and sex (male/female/unknown), VE was 14% (95% CI: −71 to 57).
f Excluding the province of British Columbia, none of the influenza B VE estimates were higher and all remained within 5% (absolute) of those displayed.

subtype, 551 (77%) were A(H1N1)pdm09 and 164 (23%) were A(H3N2). Among the 683 influenza B detections, lineage was known for 262 (38%), of which 261 (99%) were B/Victoria (Figure).

### Participant characteristics
As in prior seasons [6,8], most (61%; 1,718/2,808) participants were adults 20–64 years old (Table 1). Among test-negative controls, 21% (295/1,397) had one or more comorbidities, which is comparable to last season’s interim report (22%) and consistent with other surveillance data indicating >20% of Canadians live with a major chronic disease [11]. Vaccination ≥ 2 weeks before ILI onset was reported by 29% (399/1,397) of controls overall and 26% (229/877) of those 20–64 years old, also similar to last season’s interim report (27% and 24%, respectively) [8].

### Vaccine effectiveness and virological characterisation
The 2019/20 influenza VE overall was 58% (95% CI: 47 to 66), reflecting the preponderance of contributing adults 20–64 years old (55%; 95% CI: 41 to 66), with higher point estimates among children 1–19 years (74%; 95% CI: 59 to 84) but lower among adults aged ≥65 years (18%; 95% CI: −59 to 58) (Table 1).

**Influenza A(H1N1)pdm09**
VE against influenza A(H1N1)pdm09 was 44% (95% CI: 26 to 58) overall: 63% (95% CI: 25 to 81) in children 1–19 years old and 39% (95% CI: 14 to 56) in adults 20–64 years old (Table 1). Of the 551 influenza A(H1N1)pdm09 viruses detected by the SPSN and contributing to VE analyses, 287 (52%) were sequenced. This showed that none of the A(H1N1)pdm09 viruses belonged to the same clade as the vaccine strain (6B.1A1). Instead, 285/287 (99%) viruses belonged to
### Table 2

| Clades with defining substitutions (antigenic site) | Number of viruses |
|---------------------------------------------------|-------------------|
| **Influenza A(H1N1)pdm09**                       | N=287             |
| 6B.1A   = 6B + $+574$R (Cb) + S162N (Sa)(+CHO) + S164T (Sa) + I216T + I295V | n=0               |
| 6B.1A1 = 6B.1A + S183P                             | n=0               |
| 6B.1A5 = 6B.1A + S183P + N260D                     | n=1               |
| 6B.1A5A = 6B.1A5 + N129D + T185I (Sb)             | n=245             |
| + D187A (Sb)(RBS) + Q189E (Sb)                    | 99                |
| + D187A (Sb)(RBS) + Q189E (Sb) + A73E (Cb) + T120I | 16                |
| + K130N + N156K (Sa) + L161I (Sa) + V250A + HA2: T147A | 108              |
| 6B.1A5B = 6B.1A5 + E235D (Ca1) + HA2: V193A       | n=39              |
| + K160M (Sa) + T216K                               | 2                 |
| + K160M (Sa) + T216K + K130N + H296N               | 15                |
| + K160M (Sa) + T216K + K130N + H296N + P137S (Ca2) + V272I | 22               |
| 6B.1A7 = 6B.1A + K302T + HA2: I77M + N169S + E179D | n=2               |
| + E68D + S121N + L161I (Sa) + T120A               | 1                 |
| **Influenza A(H3N2)**                             | N=80              |
| 3C.2a1b   = 3C.2a + N121K (D) + N121K (D) + K29R (E) + H311Q (C) + HA2: I77V + G155E | n=0               |
| 3C.2a1b/T135K = 3C.2a1b + E62G (E) + R142G (A) + T135K (A) + HA2: V200l | n=44              |
| + K83E (E) + Y94N (E)                             | 4                 |
| + Q197R (B) + S219F (D) + HA2: V18M               | 3                 |
| + Q197R (B) + S219F (D) + HA2: V18M + K207R (D)  | 32                |
| + Q197R (B) + S219F (D) + HA2: V18M + K207R (D) + S144R (B) | 4                |
| 3C.2a1b/T135K = 3C.2a1b + E62G (E) + R142G (A) + T135K (A)(RBS)(−CHO) + T128A (B)(−CHO) | n=31              |
| + S137F (A)(RBS) + G186D (B) + D190N (B)(RBS) + F193S (B) + S198P (B) | 19               |
| + S137F (A)(RBS) + G186D (B) + D190N (B)(RBS) + F193S (B) + S198P (B) | 19               |
| + A138S (A)(RBS) + T128A (B)(−CHO) + R142G (A) + T135K (A)(RBS)(−CHO) + T128A (B)(−CHO) | n=31              |
| + S137F (A)(RBS) + G186D (B) + D190N (B)(RBS) + F193S (B) + S198P (B) | 19               |
| + S137F (A)(RBS) + G186D (B) + D190N (B)(RBS) + F193S (B) + S198P (B) | 19               |
| + A138S (A)(RBS) + T128A (B)(−CHO) + R142G (A) + T135K (A)(RBS)(−CHO) + T128A (B)(−CHO) | n=31              |
| + S137F (A)(RBS) + G186D (B) + D190N (B)(RBS) + F193S (B) + S198P (B) | 19               |
| + A138S (A)(RBS) + T128A (B)(−CHO) + R142G (A) + T135K (A)(RBS)(−CHO) + T128A (B)(−CHO) | n=31              |
| + S137F (A)(RBS) + G186D (B) + D190N (B)(RBS) + F193S (B) + S198P (B) | 19               |
| 3C.3a   = 3C.3 + L3I + S91N (E) + A138S (A)(RBS) + N144K (A)(−CHO) + F159S (B) + F193S (B) + N225D (RBS) + K326R + HA2: D160N | n=5               |
| 3C.3a = 3C.3 + L3I + S91N (E) + A138S (A)(RBS) + N144K (A)(−CHO) + F159S (B) + F193S (B) + N225D (RBS) + K326R + HA2: D160N | n=5               |
| **Influenza B/Victoria lineage**                  | N=260             |
| V1A.1 (Δ2) = V1A + Δ162–163 (160-loop) + D129G (120-loop) + I180V + HA2: R151K | n=1               |
| V1A.3 (Δ3) = V1A + Δ162–164 (160-loop) + I180V + K209N | n=0               |
| V1A.3B (Δ3) = V1A + Δ162–164 (160-loop) + K136E (120-loop) | n=259             |
| + G133R (120-loop) + E128K (120-loop)             | 117               |
| + R133K (120-loop) + E128K (120-loop)             | 79                |
| + N150K (150-loop) + G184E + N197D (190-helix)(−CHO) + R279K | 1               |
| **Influenza B/Yamagata lineage**                  | N=1               |
| Clade 3a = Clade 3 + L172Q + D232N (230-region)(+CHO) + M251V | n=1               |

| HA: haemagglutinin; (+/− CHO) signifies gain/loss of potential N-linked glycosylation; (RBS) signifies substitution affecting the receptor binding site. |

The number of viruses belonging to the specified influenza A subtype or B lineage are shown in bolded font as N=number. The number of viruses belonging to a parent genetic group are also shown in bold as n=number. The number of viruses within that parent group bearing the additional substitutions specified are shown in normal font. Specified substitutions are for HA1 unless specified as for HA2.

a Indicates 2019/20 trivalent influenza vaccine strain.
b Clade 3C.2a defined by 3C + L3I + N144S (A) + N145S (A) + F159Y (B) + K160T (B) (+CHO) + N225D (RBS) + Q311H (C) + HA2: D160N.
c Clade 3C.3 defined by 3C + T128A(B)(−CHO) + R142G (A) + N145S(A).
d Indicates 2019/20 quadrivalent influenza vaccine strain. SPSN virus bears additional substitutions in relation to the vaccine strain as shown.
clade 6B.1A5 of which 245 (86%) further sub-clustered with 6B.1A5A and 39 (14%) with 6B.1A5B (Table 2).

With restriction to the 245 influenza A(H1N1)pdm09 cases belonging to clade 6B.1A5A, the VE was 49% (95% CI: 26 to 65). Among the 6B.1A5A viruses, two distinct genetic sub-groups were observed. This includes 115 (47%) viruses that bore additional antigenic site Sb substitutions, namely D187A (Sb)(RBS) and Q189E (Sb), and for which VE was 61% (95% CI: 30 to 78). The second sub-group includes 108 (44%) viruses that instead bore new antigenic site Sa substitutions, namely N156K (Sa) and L161I (Sa), for which VE was 45% (95% CI: 6 to 68). All 39 of the 6B.1A5B viruses also showed drift, acquiring K160M (Sa) and some also P137S (Ca2) substitution (Table 2). VE against clade 6B.1A5B viruses was 26% (95% CI: −69 to 67). However, these clade-specific analyses are based on limited convenience subsets of the A(H1N1)pdm09 cases, requiring cautious interpretation in this interim analysis.

Of 87/551 (16%) A(H1N1)pdm09 viruses characterised by HI assay, 41 (47%) were antigenically distinct from the vaccine strain. Sequence information was available for 39/41 and all belonged to the 6B.1A5A sub-group bearing the new Sa substitutions.

**Influenza A(H3N2)**

VE against influenza A(H3N2) was 62% (95% CI: 37 to 77) overall (Table 1). Of 80/164 (49%) A(H3N2) viruses sequenced, just five clustered with the clade 3C.3a vaccine strain. Most (75/80; 94%) belonged instead sequenced, just five clustered with the clade 3C.3a lineage which has not otherwise contributed to the V1A.3B viruses, notably the 6B.1A5A sub-cluster, have predominated so far in Canada and Europe [3]. In addition to S183P, 6B.1A5A viruses bear T185I (Sb) and about half (47%) additionally bear other antigenic site Sb substitutions (D187A (Sb)(RBS) and Q189E (Sb)), with residue 187 in particular recognised for its potential role in the emergence of escape mutants [14-17]. Nearly half (44%) of 6B.1A5A viruses have instead acquired novel substitutions in antigenic site Sa (N156K (Sa) and L161I (Sa)). This recent accumulation of several substitutions clustered within pivotal antigenic sites Sa and Sb suggests immune selection pressure [14,15]; consistent with that, a substantial proportion of A(H1N1)pdm09 viruses characterised by the SPSN (41/87; 47%) and in Canada overall (89/235; 38%) [1] this season have been antigenically distinct from the vaccine strain.

Almost all influenza B viruses belonged to the B/Victoria lineage which has not otherwise contributed much since the 2015/16 season [1,18]. Children are most affected by influenza B, particularly B/Victoria-lineage viruses [19,20], and this may be evident in the over-representation of children 1–19 years old among unvaccinated influenza B cases (307/623; 49%) compared with controls (284/998; 28%) or with the population of SPSN provinces (20%) overall [21]. Whereas the 2019/20 vaccine is a double deletion V1A.1 (Δ2) strain, virtually all viruses collected and sequenced by the SPSN were instead triple deletion V1A.3B (Δ3) variants, as also noted from Europe [3] and the United States (US) [4]. The majority of B/Victoria-lineage viruses HI-characterised by the SPSN (57/58), and otherwise in Canada (157/173; 91%) [1] have also been antigenically distinct from the vaccine strain. Notwithstanding that vaccine mismatch, we found substantial VE of 69% overall and 77% in children. As previously highlighted, influenza B immuno-epidemiology is complex with cohort effects and cross-lineage interactions that may also play a role in vaccine protection [18,19,22-24].
Most but not all A(H3N2) viruses successfully characterised by HI assay to date in Canada (35/41; 85%) [1] and in Europe (11/17; 65%) [3] have been antigenically distinct from the egg-adapted vaccine strain, and in the US most (39/69; 57%) have also been distinct from the cell-passaged vaccine strain based upon focus reduction assay [4]. In that regard, the VE of 62% we report may be unexpected. Effectiveness of the 2019/20 clade 3C.3a vaccine against predominant 3C.2a1b viruses is higher than observed for the 2018/19 clade 3C.2a1 vaccine against late-season A(H3N2) viruses overall (47%) or in clade-specific analyses against co-circulating 3C.2a1b (27%) or 3C.3a (~32%) viruses [25]. Antibody induced to clade 3C.3a may be more cross-reactive than that of antibody induced to clade 3C.2a [26,27], and recent parallel substitutions shared between 3C.3a and 3C.2a1b/F135K viruses (e.g. A138S, F193S) may further contribute. An immunological cohort effect (i.e. imprint-regulated effect of vaccine; I-ReV) was hypothesised last season to explain the paradoxical negative VE for the 3C.2a1 vaccine against 3C.3a viruses, notably among adults 35-54 years of age [25,28,29]. Whether the I-ReV hypothesis may also apply, but in reverse, to explain this season’s protective VE for 3C.3a vaccine against 3C.2a1 viruses requires greater sample size to explore. We highlight that only once previously in the past decade (2011/12) has the SPSN reported an overall VE exceeding 50% for A(H3N2) viruses [6]. As such, and particularly noting the limited sample size of A(H3N2) cases, our interim estimate of 2019/20 A(H3N2) VE requires cautious interpretation pending further end-of-season evaluation.

Limitations of the current analysis include its observational design for which residual bias and confounding cannot be ruled out. Sample size considerations preclude further stratification (e.g. by additional age and/or genetic sub-groups, or prior vaccination history) but will be attempted end-of-season. Our analyses reflect specimens and data collected as at 1 February 2020 but may change towards the end of the ongoing epidemic.

Conclusions
The 2019/20 VE reported by the Canadian SPSN suggests that, among non-elderly individuals, about six of 10 cases of medically-attended febrile respiratory illness due to influenza might have been prevented by vaccination. Such substantial vaccine protection despite antigenic mismatch, notably to circulating influenza A(H3N2) and B/Victoria viruses, invites exploration of other factors potentially contributing to VE.

Acknowledgements
The authors gratefully acknowledge the contribution of sentinel sites whose regular submission of specimens and data provide the basis of our analyses. We wish to acknowledge the administrative, coordination and data entry support in each participating province including: Shinhye Kim for the British Columbia Centre for Disease Control; Yvonne Efegoma, Sara Orenstein, and Samiha Mohns for TARRANT in Alberta; Kathleen Parris for Public Health Ontario; and Sophie Auger for the Institut national de santé publique du Québec. We acknowledge the laboratory support provided by Kara Schultz and additionally thank those who provided laboratory and technical support in each province at the British Columbia Centre for Disease Control Public Health Laboratory; the Public Health Laboratory (ProVLab), the Alberta Precision Laboratories; the Public Health Ontario Laboratory; the Laboratoire de santé publique du Québec (LSPQ); and the National Microbiology Laboratory (NML). Finally, we acknowledge the GISAID EpiFlu Database (www.gisaid.org) for serving as a repository for sharing viral genetic data and facilitating related analyses.

Funding statement
Funding was provided by the British Columbia Centre for Disease Control, Alberta Health and Wellness, Public Health Ontario, Ministère de la santé et des services sociaux du Québec, and the Public Health Agency of Canada. The views expressed herein do not necessarily represent the view of the Public Health Agency of Canada. Funders had no role in data analysis or interpretation or in the decision to publish.

Conflict of interest
DMS is Principal Investigator on grants received from the Public Health Agency of Canada in support of this work. GDS has received grants for investigator-initiated studies unrelated to influenza vaccine from Pfizer and provided paid expert testimony for the Ontario Nurses Association, the Quebec Ministry of Justice and GSK. MK has received research grants from Roche, Siemens and Hologic for unrelated studies. Other authors have no conflicts of interest to declare.

Authors’ contributions
Principal investigator (study planning, design): DMS. Co-investigators (epidemiological data assembly): JAD (Alberta), MM (Ontario) and GDS (Québec). Co-investigators (laboratory diagnostic data assembly): AJ and MK (British Columbia), MC (Alberta), JBG (Ontario), HC (Québec) and NB and YL (National Microbiology Laboratory). Additional laboratory and epidemiological support: RO (Ontario). Genomic analyses: SS. Epidemiological analyses: DMS and MZ. Preparation of first draft: DMS. Draft revision and approval: all.

References
1. Public Health Agency of Canada (PHAC). Weekly influenza reports 2019-2020 season. FluWatch report: January 26 to February 1, 2020 (Week 5). Ottawa: PHAC. [Accessed 16 Feb 2020]. Available from: https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html
2. European Centre for Disease Prevention and Control (ECDC). World Health Organization (WHO) Regional office for Europe. Flu News Europe, Joint ECDC–WHO weekly influenza update, week 05/2020. [Accessed 16 Feb 2020]. Available from: http://fluinwesturope.org/Archives
3. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization, December 2019. Stockholm: ECDC, [Accessed 1 Feb 2020]. Available from: https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characterisation-december-2019
4. Centers for Disease Control and Prevention (CDC), FluvView: Weekly Influenza surveillance report. 2019-2020 influenza season week 5 ending February 1, 2020. Atlanta: CDC [Accessed 16 Feb 2020]. Available from: https://www.cdc.gov/flu/weekly/pastreports.htm
5. World Health Organization (WHO). Influenza updates for 2019-2020 season. Geneva: WHO. [Accessed 1 Feb 2020]. Available from: https://www.who.int/influenza/surveillance_monitoring_updates/en/
6. Canadian Sentinel Practitioner Surveillance Network (SPSN). Influenza vaccine effectiveness estimates % (95% CI), 2004-05 to 2018-19 seasons. Vancouver: British Columbia Centre for Disease Control; [Accessed 1 Feb 2020]. Available from: https://www.bccdc.ca/resource-library/Documents/Statistics%20and%20Research/Publications/Epid/Influenza%20and%20Respiratory/SPSN_VE_By_Year_Table.pdf

7. Katz JM, Hancock RM, Xu X. Serological markers for influenza diagnosis, surveillance and vaccine effectiveness. Expert Rev Anti Infect Ther. 2011;9(6):669-683. doi: https://doi.org/10.1586/eri.11.51 PMID: 21692672.

8. Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olska R, et al. Effectiveness estimates of 2018-19 influenza vaccine effectiveness against influenza A(H3N2) pdm09, Canada, January 2019. Euro Surveill. 2019;24(4):1900055. https://doi.org/10.2807/1560-7917.ES.2019.24.4.1900055 PMID: 3069523.

9. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO; [Accessed 1 Feb 2020]. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/en/.

10. Worldwide Influenza Centre, Francis Crick Institute. September 2019 interim report. London: Francis Crick Institute; [Accessed 1 Feb 2020]. Available from: https://www.crick.ac.uk/partnerships/worldwide-influenza-centre/annual-and-interim-reports/.

11. Public Health Agency of Canada (PHAC). How healthy are Canadians? A trend analysis of the health of Canadians from a healthy living and chronic disease perspective. Ottawa: PHAC; [Accessed 1 Feb 2020]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/how-healthy-canadians.html.

12. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Beyond antigenic match: possible agent-host and immunomediational influences on influenza vaccine effectiveness during the 2015-2016 season in Canada. J Infect Dis. 2017;216(2):1487-500. doi: https://doi.org/10.1093/infdis/jix226 PMID: 2902166.

13. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season. J Infect Dis. 2015;212(5):726-39. doi: https://doi.org/10.1093/infdis/jiv177 PMID: 2595245.

14. Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, et al. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J Clin Invest. 2018;128(11):4992-6. doi: https://doi.org/10.1172/JCI122895 PMID: 30188868.

15. Rudneva I, Ignatieva A, Timofeeva T, Shilov A, Kushch A, Timofeyeva O, et al. Escape mutants of pandemic influenza A/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin. Virus Res. 2012;166(1-2):61-7. doi: https://doi.org/10.1016/j.virusres.2012.03.003 PMID: 22459010.

16. Tsibane T, Eikert DC, Krause JC, Martinez O, Crowe JE Jr, Wilson IA, et al. Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog. 2012;8(12):e1003067. doi: https://doi.org/10.1371/journal.ppat.1003067 PMID: 23236279.

17. Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Misaki R, et al. Emerging antigenic variants at the antigenic site SB in pandemic A(H1N1)2009 influenza virus in Japan detected by a human monoclonal antibody. PLoS One. 2013;8(10):e77892. doi: https://doi.org/10.1371/journal.pone.0077892 PMID: 24147093.

18. Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Vaccine effectiveness against lineage-matched and mismatched influenza B viruses across 8 seasons in Canada, 2010-2011 to 2017-2018. Clin Infect Dis. 2019;68(5):1754-7. doi: https://doi.org/10.1093/cid/ciy876 PMID: 30780822.

19. Gaglani M, Vasudevan A, Raiyani C, Murthy K, Chen W, Reis M, et al. Effectiveness of trivalent and quadrivalent inactivated vaccines against influenza B in the United States, 2011-2012 to 2015-2016. Clin Infect Dis. 2020;61(suppl_2):S160-102. doi: https://doi.org/10.1093/cid/ciaa102 PMID: 32006430.

20. Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Winter AL, Rhéaume C, et al. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One. 2012;7(6):e38929. doi: https://doi.org/10.1371/journal.pone.0038929 PMID: 22745690.

21. License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2020.